doi: 10.7326/0003-4819-138-4-200302180-00027.
Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction
- PMID: 12585846
- DOI: 10.7326/0003-4819-138-4-200302180-00027
Item in Clipboard
Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction
Ann Intern Med.
.
No abstract available
Similar articles
-
Drugs approved for opiate dependence.FDA Consum. 2003 Jan-Feb;37(1):6. FDA Consum. 2003. PMID: 12625293 No abstract available.
-
Office-based practice and opioid-use disorders.N Engl J Med. 2003 Sep 4;349(10):928-30. doi: 10.1056/NEJMp038126. N Engl J Med. 2003. PMID: 12954740 No abstract available.
-
In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.Med Lett Drugs Ther. 2013 Oct 14;55(1427):83. Med Lett Drugs Ther. 2013. PMID: 24129113 No abstract available.
-
Buprenorphine maintenance: a new treatment for opioid dependence.Cleve Clin J Med. 2007 Jul;74(7):514-20. doi: 10.3949/ccjm.74.7.514. Cleve Clin J Med. 2007. PMID: 17682629 Review.
-
Recent advances in the treatment of opiate addiction.Curr Psychiatry Rep. 2004 Oct;6(5):339-46. doi: 10.1007/s11920-004-0020-1. Curr Psychiatry Rep. 2004. PMID: 15355756 Review.
Cited by
-
Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.J Natl Med Assoc. 2012 Jul-Aug;104(7-8):342-50. doi: 10.1016/s0027-9684(15)30175-9. J Natl Med Assoc. 2012. PMID: 23092049 Free PMC article. Review.
-
Effects of monoamine oxidase inhibitors on cocaine discrimination in rats.Behav Pharmacol. 2006 Mar;17(2):151-9. doi: 10.1097/01.fbp.0000197459.08892.b5. Behav Pharmacol. 2006. PMID: 16495723 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
